Medicenna Announces Filing of Final Short Form Prospectus
Ontario and Houston, Texas--(Newsfile Corp. - December 17, 2018) - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has filed a (final) short form prospectus (the "Prospectus") which has been receipted by the regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario, in connection with the marketed offering (the "Offering") of units of the Company...
2018-12-17 5:41 PM EST
Medicenna Announces Pricing of Marketed Offering of Units
Ontario and Houston, Texas--(Newsfile Corp. - December 14, 2018) - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce today that it has priced its previously announced marketed offering (the "Offering") of units of the Company ("Units"). The Company intends to issue a minimum of 4,000,000 Units and a maximum of 6,000,000 Units at a price of CDN$1.00 per Unit for minimum gross proceeds of...
2018-12-14 8:06 PM EST
IIROC Trade Resumption - Medicenna Therapeutics Corp.
Vancouver, British Columbia--(Newsfile Corp. - March 7, 2017) - Trading resumes in: Company: Medicenna Therapeutics Corp.
2017-03-07 4:17 PM EST